The extensions of coronavirus-induced lockdown and unimpressive fiscal stimulus would lead to further increase in slippages and credit costs for the Indian banks. With the extended moratorium and Rs 3 lakh crore government package for SMEs, which would help in pushing back SME NPAs, will also increase slippage and credit costs for FY22E, Credit Suisse said. Due to increased slippage and credit costs, the brokerage has cut FY21/22E earnings and target price of banks by 10-20 percent.

The share price of Ujjivan Financial Services rallied on Thursday after the company reported a jump of 80 percent in its consolidated net profit.

The Sensex ended 595 points higher at 32,200 while the Nifty50 rose 175 points to settle at 9,490.

Sun Pharma in March quarter FY20 posted a consolidated profit of Rs 399.8 crore. It registered a decline of 37.1 percent year-on-year due to a one-time loss of Rs 260.6 crore. However, consolidated revenue during the quarter rose 14.3 percent year-on-year to Rs 8,184.9 crore, beating CNBC-TV18 estimate of Rs 8,015.8 crore. The pharmaceutical giant's stock rose over 1 percent after the earnings announcement. So should you buy, sell, or hold the stock post Q4? Here's what brokerages say: